- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01036490
Exercise in Obese Diabetic Patients With Chronic Kidney Disease (EX-ODCKD)
Structured Exercise in Obese Diabetic Patients With Chronic Kidney Disease
Visão geral do estudo
Descrição detalhada
Patients with type 2 diabetes, obesity, and chronic kidney disease (CKD) are generally physically inactive, have a high mortality rate, and may benefit from an exercise program. However, there have been no randomized controlled trials to determine the benefits of exercise training in this population. This study seeks to substantiate the hypothesis that increasing energy expenditure by exercise training in the obese diabetic patient with CKD will result in the following benefits:
- Renal benefits, including reduction in proteinuria and stabilization of glomerular filtration rate (GFR)
- Cardiovascular benefits, including decreased blood pressure, decreased heart rate, and increased exercise tolerance.
- Improved glucose control (lower glycated hemoglobin), lipid control (decreased cholesterol with improved atherogenic profile)
- Improved body composition (weight loss, increased lean body mass and decreased fat mass).
- Decreased inflammation (assessed by high-sensitivity C-reactive protein), endothelial dysfunction (assessed by flow-mediated dilatation), and oxidative stress (assessed by reduced glutathione).
- Increased health-related quality of life.
In preparation for this proposal, the investigators performed a 24-week randomized controlled feasibility study comparing aerobic exercise plus optimal medical management to medical management alone in patients with type 2 diabetes, obesity (BMI > 30 kg/m2), and stage 2-4 CKD (eGFR 15-90 mL/min/1.73m2) with persistent proteinuria of > 200 mg/g. Subjects randomized to exercise underwent thrice weekly aerobic training for 6 followed by 18 weeks of supervised home exercise. The primary outcome variable was change in proteinuria. Exercise training resulted in a significant improvement in exercise duration during stress testing which persisted until 24 weeks. This was accompanied by significant decreases in resting systolic blood pressure and 24-hour proteinuria at 24 weeks. No changes were seen in the control group. The investigators concluded that exercise training in obese diabetic patients with CKD is feasible and results in a demonstrable training effect (increased exercise duration and decreased resting blood pressure). Moreover, it may decrease proteinuria and thus have a renoprotective effect.
The investigators now propose a larger-scale randomized controlled trial to determine the effects of exercise on renal functions, cardiovascular fitness, inflammation, and oxidative stress in diabetic patients with CKD. This will be a 52-week randomized study based on the investigators' pilot study design with some modifications. As opposed to the 6-week training period and 18-week home exercise period utilized in the pilot study, subjects randomized to exercise will undergo 12 weeks of intensive exercise training in the exercise laboratory followed by 40 weeks of supervised home exercise training (total duration of study 1 year). Moreover, due to recent recommendations that resistance training be incorporated into exercise training regimens in type 2 diabetic patients, the investigators will incorporate resistance (strength) training in this proposal. The primary outcome variable will be change in proteinuria at 12 and 52 weeks. Secondary outcome variables will be change in albuminuria and estimated glomerular filtration rate (eGFR) at 12 and 52 weeks. In addition, the investigators will measure blood pressure (BP), glycated hemoglobin, lipid profile, C-reactive protein (CRP) levels, body weight and composition, endothelial dysfunction (by flow-mediated dilatation), and Quality of Life (QoL) evaluations. The Index of Coexistent Diseases (ICED) to measure comorbidities to determine if comorbid conditions had any influence on the outcomes of the study. The Center for Epidemiologic Studies Depression Scale (CES-D) will also be used to determine the influence of depression (covariate) on study outcomes and adherence with the study objectives.
This study will directly address the effects of a structured exercise program in a patient population at high risk for cardiovascular complications. The investigators will specifically address the novel idea that exercise will not only improve cardiovascular fitness but will also ameliorate the renal complications resulting from diabetes.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Illinois
-
Hines, Illinois, Estados Unidos, 60141-5000
- Edward Hines Jr. VA Hospital, Hines, IL
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Diabetes mellitus
- CKD Stages 2-4
- BMI > 30
- Persistent proteinuria (urine protein/creatinine > 200 mg/g for > 3 mo)
- On treatment with ACE inhibitor or ARB
- On treatment with aspirin
- On treatment with statin (if LDL > 100)
Exclusion Criteria:
- Symptomatic neuropathy/retinopathy
- Positive stress test due to coronary arterial disease
- Symptomatic cardiovascular disease
- Congestive heart failure (New York Heart Association Class III or IV)
- Chronic obstructive pulmonary disease (FEV1 < 50% predicted and/or requires supplemental oxygen support during exercise)
- Complaints of angina during the stress test
- Cerebrovascular disease/cognitive impairment
- Renal transplant
- Inability to walk on the treadmill
- Any unforeseen illness or disability that would preclude exercise testing or training
- Participation in a formal exercise program within the previous 12 weeks
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Ao controle
Grupo de controle
|
|
|
Experimental: Exercise
Exercise Group
|
Exercise training for 12 weeks followed by home exercise for 40 weeks
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Change in Proteinuria
Prazo: 12 weeks minus baseline
|
12 weeks minus baseline
|
|
Change in Proteinuria
Prazo: 52 weeks minus baseline
|
52 weeks minus baseline
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Change in Albuminuria
Prazo: 12 weeks minus baseline
|
12 weeks minus baseline
|
|
Change in Albuminuria
Prazo: 52 weeks minus baseline
|
52 weeks minus baseline
|
|
Change in Estimated Glomerular Filtration Rate (eGFR)
Prazo: 12 weeks minus baseline
|
12 weeks minus baseline
|
|
Change in Estimated Glomerular Filtration Rate (eGFR)
Prazo: 52 weeks minus baseline
|
52 weeks minus baseline
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Eileen G. Collins, PhD RN, Edward Hines Jr. VA Hospital, Hines, IL
- Investigador principal: David J Leehey, Edward Hines Jr. VA Hospital, Hines, IL
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- F7264-R
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .